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We read with interest the article recently published in 
Arthritis Research & Th  erapy by Kreiner and Galbo [1] 
that reported a very modest beneﬁ  t of etanercept mono-
therapy in polymyalgia rheumatica (PMR). Th   ere is some 
evidence that TNFα can be found in the lesions of giant 
cell arteritis (GCA) [2]. However, two previous 
randomised controlled trials [3,4] showed no beneﬁ  t of 
TNFα inhibition in the treatment of PMR/GCA. We 
report for the ﬁ  rst time the development of PMR and 
GCA in two patients undergoing treatment with anti-
TNFα drugs. Th   is suggests that the underlying 
immunopathology of GCA/PMR is not driven by TNFα 
and casts further doubt on the likely usefulness of TNFα 
blockade in these conditions.
Th  e ﬁ   rst patient was a woman aged 72 years with 
ankylosing spondylitis. Adalimumab was commenced in 
July 2006 with good eﬀ  ect. On review in August 2009 she 
reported increasing pain and stiﬀ  ness in her shoulders 
and pelvic girdle. Her ‘usual’ ankylosing spondylitis-
related lower back pain remained well controlled. Her 
new symptoms did not respond to diclofenac; however, 
within 48 hours of starting prednisolone 15 mg once 
daily there was a marked and sustained improvement. 
Th   is was maintained until in subsequent months 
prednisolone was reduced to 5 mg, when recurrence of 
symptoms again responded promptly to an increased 
dose. Th  e rapid response to glucocorticoids and the 
sensitivity to changes in dose strongly support the clinical 
diagnosis of PMR.
Th   e second patient, a woman aged 75 years, was treated 
with adalimumab 40 mg fortnightly, and daily leﬂ  uno-
mide 10 mg and prednisolone 7.5 mg for seropositive 
erosive rheumatoid arthritis. Initially, she responded well 
to adalimumab but 8 months later signiﬁ  cantly elevated 
erythrocyte sedimentation rate (84 mm/h) and C-reactive 
protien (87 mg/L) were noted on monitoring. On review 
there was no worsening of joint pain, and she did not 
volunteer other symptoms. However, direct questioning 
revealed a worsening headache, jaw ache on chewing, 
and visual disturbance. A clinical diagnosis of GCA was 
made and her glucocorticoid dose increased to 60 mg 
daily, result  ing in a rapid improvement in her symptoms. 
Temporal artery biopsy revealed changes typical of GCA.
Our two cases, who developed GCA and PMR, respec-
tively, whilst on anti-TNFα therapy, support the opinion 
expressed by Luqmani [5] that use of anti-TNFα in the 
treatment of these conditions is unlikely to be successful. 
Eﬀ   orts should instead be focused on other potential 
cytokine targets, such as interleukin-6, and on optimal 
use of glucocorticoids and appropriate measures to 
minimise their inevitable side eﬀ  ects.
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